Switzerland-based GlycoVaxyn AG, a specialist vaccine developer, has been sold by its venture capital investors to GlaxoSmithKline Plc in a deal that values the company at $212 million. The company’s investors include Sofinnova Partners, Index Ventures and Edmond de Rothschild Investment Partners.
